Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 30, Issue 1, 2002, Pages 33-40

  Lange, Christoph G ^a   Lederman, Michael M ^a   Sierra Madero, Juan ^a   Medvik, Kathy ^a   Asaad, Robert ^a   Pacheko, Christina ^a   Carranza, Claudia ^a   Valdez, Hernan ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

CD4+ nadir; DTH; HAART; HIV; HIV p24; Immune function; Lymphoproliferation; Phenotype

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; CD28 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAG PROTEIN; HLA DR ANTIGEN;

ADULT; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DISEASE ASSOCIATION; HELPER CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; MEMORY CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS REPLICATION;

EID: 0036570559     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200205010-00005     Document Type: Article

References (54)

1. Changing patterns of mortality across Europe in patients infected with HIV-1
2. AIDS across Europe, 1994-98: The EuroSIDA study
3. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
4. Changing spectrum of mortality due to human immunodeficiency virus: Analysis of 260 deaths during 1995-1999
5. + T lymphocytes
6. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease
7. + T cell homeostasis and function in advanced HIV disease
8. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315
9. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team
10. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response
11. + T-lymphocyte nadir and the effect of highly active antiretroviral therapy (HAART) on phenotypic and functional immune restoration in HIV-1 infection
12. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
13. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens
14. Human immunodeficiency virus 1 protease inhibitors in clinical practice: Predictors of virological outcome
15. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease
16. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection
17. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: Age inversely predicts naive CD4 cell count increase
18. Comparison of T-cell subsets' reconstitution after 12 months of highly active antiretroviral therapy initiated during early versus advanced states of HIV disease
19. Measurement of delayed skin-test responses
20. Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease
21. Functional T cell reconstitution and human immunodeficiency virus-1- specific cell-mediated immunity during highly active antiretroviral therapy
22. Antigen-specific T-lymphocyte proliferative responses during highly active antiretroviral therapy (HAART) of HIV-1 infection
23. Proliferative responses to human immunodeficiency virus type 1 (hiv-1) antigens in HIV-1infected patients with immune reconstitution
24. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
25. Low viral load and HLA-DRI predict long-term persistence of a CD4 T helper-1 response to HIV in long-term nonprogressors (LTNP)
26. Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression
27. Preserving HIV-1 specific T-cell help. Will it preserve progression?
28. Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART
29. + T cell proliferation
30. Is there a role for immunotherapy in controlling HIV infection?
31. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy
32. When to start highly active antiretroviral therapy in chronically HIV-1infected patients: Evidence from the ICONA study
33. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: Results from the EuroSIDA study
34. + T-cell restoration after suppressive antiretroviral therapy
35. Increased levels of activated subsets of CD4 T cells add to the prognostic value of low CD4 T cell counts in a cohort of HIV-infected drug users
36. + T cell levels: Results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort study
37. + T-cell losses using adjusted correlative analyses
38. + cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression
39. Immune reconstitution in HIV infection
40. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection
41. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements
42. Expansion of T cells negative for CD28 expression in HIV infection: Relation to activation markers and cell adhesion molecules, and correlation with prognostic markers
43. Expression of co-stimulatory molecule CD28 on T cells in human immunodeficiency virus type 1 infection: Functional and clinical correlations
44. + T cells down-regulates the expression of CD28: Effect on T cell activation and cytokine production
45. CD28-B7 interactions in T-cell activation
46. Low T cell reactivity to combined CD3 plus CD28 stimulation is predictive for progression to AIDS: Correlation with decreased CD28 expression
47. Immune function and phenotype before and after highly active antiretroviral therapy
48. Immune reconstitution in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy: A cohort study
49. Lymphocyte proliferative responses to HIV-1 envelope and core antigens by infected and uninfected adults and children
50. Helper and cytotoxic T cell responses of HIV type 1-infected individuals to synthetic peptides of HIV type 1 Rev
51. HIV-specific lymphoproliferative responses in asymptomatic HIV-infected individuals
52. T cells from individuals in advanced stages of HIV-1 infection do not proliferate but express activation antigens in response to HIV-1-specific antigens